Antimicrobial resistance

**Agenda item 13.5**

**Document A74/10 Rev.1**

Thank you for the opportunity to deliver this statement on behalf of UICC, supported by NCD Alliance.

We welcome the updates to the report by the Director-General on addressing antimicrobial resistance (AMR). There has been substantial progress in cancer care in the past decades, with key advances in innovative treatments. However, the growing threat of AMR could threaten the progress that has been made thus far in cancer treatments, affect the viability of safe surgery and therapies, and adversely affect treatment outcomes, with cancer patients at risk of infection.

In order to continue to improve cancer care and NCD outcomes it will be critical to accelerate actions tackling AMR and, we urge Member States to:

- Participate in and ensure the provision of data into the Global Antimicrobial Resistance Surveillance System (GLASS) to ensure global data sharing and addressing the issue collectively.
- Adopt multisectoral policies to ensure access to and rational use of antimicrobials and diagnostics in addressing the growing problem of drug resistance, especially now.
- Address the issue of substandard and falsified medicines, by ensuring the quality of antimicrobials which is an essential component towards achieving stewardship goals.
- Engage in multisectoral partnerships and sustained investment to address the increased need of R&D for novel antimicrobials, and rapid diagnostic tests.
- Engage the cancer and NCD community, infectious diseases groups and other relevant stakeholders to collaborate in raising awareness of AMR, sharing of best practises and capacity building for R&D for new antimicrobials and diagnostics.